泰莎基因治疗
TSHA
3.62
-0.11
-2.95%
泰莎基因治疗
US · TSHA
#3015 按市值排名
上市于 2020
3.62
-0.11
-2.95%
实时 - 追踪5344个代码 - 心跳于5秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了5.3个百分点。
机构持股
- 机构持股比例
- 93.68% -5.31pp
- 机构数量
- 245 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund35.53%
Hedge Fund29.74%
VC/PE Fund15.03%
Public Company10.55%
Individual/Insider8.07%
Government Pension Fund1.39%
Sovereign Wealth Fund0.69%
Private Company0.42%
Family Office/Trust0.32%
主要股东 截至 2026-06-30
Avoro Capital Advisors LLC
7.33% · 23.89M 股
RA Capital Management, L.P.
7.23% · 23.56M 股
Paul Manning
6.98% · 22.74M 股
BlackRock
6.35% · 20.69M 股
Vestal Point Capital, LP
5.96% · 19.42M 股
Morgan Stanley
4.99% · 16.24M 股
Vanguard Capital Management, LLC
4.41% · 14.38M 股
The Goldman Sachs Group, Inc.
4.17% · 13.58M 股
RTW Investments, LP
4.16% · 13.56M 股
FMR
4.09% · 13.34M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 25次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Paul Manning | Board Observer | 6.98% |
| Sean Stalfort | Independent Director | 0.63% |
| Sean Nolan | Chairperson & CEO | 0.20% |
| Kamran Alam | Chief Financial Officer | 0.14% |
| Phillip Donenberg | Independent Director | 0.07% |
| Laura Sepp-Lorenzino | Independent Director | 0.03% |
| Alison Long | Director | 0.03% |
| Sukumar Nagendran | President, Head of Research & Development and Director | -- |
| Sean McAuliffe | Chief Business Officer | -- |
| Tiger Lily Capital | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-09 | Sukumar Nagendran | President, Head of Research & Development and Director | Automatic Disposition | -200,000 | $6.24 |
| 2026-05-31 | Phillip Donenberg | Independent Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Phillip Donenberg | Independent Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-05-31 | Sean Stalfort | Independent Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Sean Stalfort | Independent Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-05-31 | Laura Sepp-Lorenzino | Independent Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Laura Sepp-Lorenzino | Independent Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-05-31 | Alison Long | Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Alison Long | Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-04-09 | Sukumar Nagendran | President, Head of Research & Development and Director | Automatic Disposition | -180,979 | $4.46 |
| 2026-04-09 | Sukumar Nagendran | President, Head of Research & Development and Director | Derivative Exercise and Sale | -19,021 | $1.71–4.46 |
| 2026-02-26 | Rumana Haque-Ahmed | Chief Regulatory Officer | Intent to Sell (Form 144) | -2,405 | $4.57 |
| 2026-02-03 | Sean McAuliffe | Chief Business Officer | Intent to Sell (Form 144) | -914 | $4.72 |
| 2026-02-03 | Kamran Alam | Chief Financial Officer | Open Market Disposition | -1,655 | $4.52 |
| 2026-02-03 | Rumana Haque-Ahmed | Chief Regulatory Officer | Intent to Sell (Form 144) | -697 | $4.72 |
| 2026-01-25 | Sean Nolan | Chairperson & CEO | Open Market Disposition | -178,101 | $4.61–4.75 |
| 2026-01-25 | Sukumar Nagendran | President, Head of Research & Development and Director | Open Market Disposition | -116,050 | $4.61–4.75 |
| 2026-01-25 | Kamran Alam | Chief Financial Officer | Open Market Disposition | -102,817 | $4.61–4.75 |
| 2026-01-22 | Sean Nolan | Chairperson & CEO | Intent to Sell (Form 144) | -168,078 | $5.09 |
| 2026-01-22 | Sukumar Nagendran | President, Head of Research & Development and Director | Intent to Sell (Form 144) | -113,824 | $5.09 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:14 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
泰莎基因治疗 讨论区 0 条评论